2,873 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Vancity Investment Management Ltd

Key Points

• Vancity Investment Management Ltd has invested approximately $1.43 million in Thermo Fisher Scientific, acquiring 2,873 shares of the company in the first quarter.
• Thermo Fisher Scientific recently reported earnings of $5.36 per share, surpassing estimates, with a revenue of $10.86 billion for the latest quarter.
• The company's stock has drawn positive attention from analysts, with a consensus rating of "Moderate Buy" and an average target price of $589.38.

Vancity Investment Management Ltd acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,873 shares of the medical research company's stock, valued at approximately $1,430,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Vanguard Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Amundi lifted its stake in Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after buying an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after buying an additional 115,463 shares during the period. Pictet Asset Management Holding SA increased its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after acquiring an additional 193,378 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Thermo Fisher Scientific by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after acquiring an additional 257,462 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 1.1%

Shares of Thermo Fisher Scientific stock traded down $5.38 during trading on Wednesday, reaching $477.03. The stock had a trading volume of 1,442,085 shares, compared to its average volume of 1,608,466. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $180.13 billion, a price-to-earnings ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The stock has a fifty day moving average price of $464.58 and a two-hundred day moving average price of $452.37. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Barclays upped their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.